BRPI0722070A2 - Inibidores de poli(adp-ribose)polimerase - Google Patents

Inibidores de poli(adp-ribose)polimerase

Info

Publication number: BRPI0722070A2
Authority: BR; Brazil
Prior art keywords: adp; ribose; poly; polymerase inhibitors; polymerase
Prior art date: 2006-12-28

Application number

BRPI0722070-7A2A

Other languages

English (en)

Inventor

Viraj B Gandhi

Vincent L Giranda

Jianchun Gong

Thomas D Penning

Gui-Dong Zhu

Original Assignee

Abbott Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-28

Filing date

2007-12-20

Publication date

2014-04-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39584870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0722070(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-20 Application filed by Abbott Lab filed Critical Abbott Lab

2014-04-08 Publication of BRPI0722070A2 publication Critical patent/BRPI0722070A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/58—1,2-Diazines; Hydrogenated 1,2-diazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Environmental Sciences (AREA)
Hematology (AREA)
Agronomy & Crop Science (AREA)
Pest Control & Pesticides (AREA)
Plant Pathology (AREA)
Dentistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI0722070-7A2A 2006-12-28 2007-12-20 Inibidores de poli(adp-ribose)polimerase BRPI0722070A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88231706P	2006-12-28	2006-12-28
PCT/US2007/088319 WO2008083027A1 (en)	2006-12-28	2007-12-20	Inhibitors of poly(adp-ribose)polymerase

Publications (1)

Publication Number	Publication Date
BRPI0722070A2 true BRPI0722070A2 (pt)	2014-04-08

Family

ID=39584870

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0722070-7A2A BRPI0722070A2 (pt)	2006-12-28	2007-12-20	Inibidores de poli(adp-ribose)polimerase

Country Status (31)

Country	Link
US (1)	US20080161280A1 (pt)
EP (2)	EP2120579B1 (pt)
JP (2)	JP5523837B2 (pt)
KR (2)	KR101491998B1 (pt)
CN (2)	CN101641014B (pt)
AU (1)	AU2007340020B2 (pt)
BR (1)	BRPI0722070A2 (pt)
CA (1)	CA2672868C (pt)
CO (1)	CO6220961A2 (pt)
CR (1)	CR10901A (pt)
DK (2)	DK2698062T3 (pt)
DO (1)	DOP2009000159A (pt)
EC (1)	ECSP099530A (pt)
ES (2)	ES2442496T3 (pt)
GT (1)	GT200900182A (pt)
HR (1)	HRP20140115T1 (pt)
HU (1)	HUE027641T2 (pt)
MX (2)	MX2009007051A (pt)
MY (2)	MY165570A (pt)
NO (1)	NO20092698L (pt)
NZ (2)	NZ598352A (pt)
PH (1)	PH12012501544A1 (pt)
PL (2)	PL2698062T3 (pt)
PT (2)	PT2698062E (pt)
RS (1)	RS53196B (pt)
RU (1)	RU2455286C2 (pt)
SG (2)	SG193664A1 (pt)
SI (2)	SI2698062T1 (pt)
TW (1)	TWI429438B (pt)
UA (1)	UA97506C2 (pt)
WO (1)	WO2008083027A1 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
GB0610680D0 (en) *	2006-05-31	2006-07-12	Istituto Di Ricerche D Biolog	Therapeutic compounds
UY30639A1 (es)	2006-10-17	2008-05-31	Kudos Pharm Ltd	Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US8466150B2 (en) *	2006-12-28	2013-06-18	Abbott Laboratories	Inhibitors of poly(ADP-ribose)polymerase
US20080280910A1 (en) *	2007-03-22	2008-11-13	Keith Allan Menear	Phthalazinone derivatives
EP2155689B1 (en)	2007-05-31	2015-07-08	Boehringer Ingelheim International GmbH	Ccr2 receptor antagonists and uses thereof
US20090023727A1 (en) *	2007-07-05	2009-01-22	Muhammad Hashim Javaid	Phthalazinone derivatives
JP2010539149A (ja) *	2007-09-14	2010-12-16	アストラゼネカアクチボラグ	フタラジノン誘導体
MX2010005070A (es) *	2007-11-15	2010-05-24	Angeletti P Ist Richerche Bio	Derivados de piridazinona como inhibidores de parp.
AR070221A1 (es)	2008-01-23	2010-03-25	Astrazeneca Ab	Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
PT2346495T (pt)	2008-10-07	2016-11-11	Astrazeneca Uk Ltd	Formulação farmacêutica 514
EP2379525B1 (en)	2008-12-19	2015-07-29	Boehringer Ingelheim International GmbH	Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
MA33053B1 (fr) *	2009-01-23	2012-02-01	Tadeka Pharmaceutical Company Ltd	Inhibiteurs de la poly(adp-ribose) polymerase (parp)
WO2010098866A1 (en)	2009-02-27	2010-09-02	Supergen, Inc.	Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
EP2459561A1 (en)	2009-07-30	2012-06-06	Takeda Pharmaceutical Company Limited	Poly (adp-ribose) polymerase (parp) inhibitors
PE20121614A1 (es)	2009-12-17	2012-12-21	Boehringer Ingelheim Int	Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2
JP2013526507A (ja)	2010-05-12	2013-06-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
WO2011141477A1 (en)	2010-05-12	2011-11-17	Boehringer Ingelheim International Gmbh	New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5647339B2 (ja)	2010-05-17	2014-12-24	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｃｒ２アンタゴニスト及びこれらの使用
JP5636094B2 (ja)	2010-05-25	2014-12-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｃｒ２受容体アンタゴニスト
WO2011151251A1 (en)	2010-06-01	2011-12-08	Boehringer Ingelheim International Gmbh	New ccr2 antagonists
JP2013532703A (ja) *	2010-08-03	2013-08-19	ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ	Ｐａｒｐ−１阻害剤および抗新生物剤を含む治療用組合せ
CN102372716A (zh)	2010-08-09	2012-03-14	江苏恒瑞医药股份有限公司	酞嗪酮类衍生物、其制备方法及其在医药上的应用
SG194138A1 (en)	2011-04-11	2013-11-29	Abbvie Inc	Parp inhibitors for the treatment of cipn
ES2871052T3 (es)	2011-05-31	2021-10-28	Rakovina Therapeutics Inc	Inhibidores tricíclicos de la poli(ADP-ribosa)polimerasa
WO2013010839A1 (en)	2011-07-15	2013-01-24	Boehringer Ingelheim International Gmbh	Novel and selective ccr2 antagonists
TWI548637B (zh) *	2011-07-26	2016-09-11	江蘇豪森藥業集團有限公司	酞嗪酮類衍生物、其製備方法及其在醫藥上的應用
EP2748166B1 (en)	2011-08-23	2018-07-11	Asana BioSciences, LLC	Pyrimido-pyridazinone compounds and use thereof
AU2012318874A1 (en) *	2011-10-06	2014-05-15	Merck Sharp & Dohme Corp.	1,3-substituted azetidine PDE10 inhibitors
CN103242273B (zh) *	2012-02-09	2015-06-03	中国科学院上海药物研究所	2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN102627620B (zh) *	2012-04-10	2015-12-16	江苏先声药物研究有限公司	一类苯并呋喃衍生物及其医药应用
CN103570725B (zh) *	2012-08-01	2017-03-22	中国科学院上海药物研究所	哌嗪并三唑类化合物及其制备方法和用途
RU2527457C2 (ru) *	2012-09-27	2014-08-27	Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран)	Ингибиторы поли(адф-рибозо)полимеразы-1 человека на основе производных урацила
JP5930452B2 (ja)	2012-12-31	2016-06-08	カディラ・ヘルスケア・リミテッド	置換フタラジン‐１（２ｈ）‐オン誘導体
BR112015023328A2 (pt)	2013-03-13	2017-07-18	Flatley Discovery Lab	compostos de piridazinona e métodos para o tratamento de fibrose cística
KR101670126B1 (ko)	2013-09-13	2016-10-27	일동제약(주)	신규 프탈라지논 유도체 및 그 제조방법
CN103772395B (zh) *	2014-01-23	2016-05-11	中国药科大学	一类具有parp抑制活性的化合物、其制备方法及用途
CN106146492A (zh) *	2015-04-17	2016-11-23	上海汇伦生命科技有限公司	杂环并咪唑类化合物、其药物组合物及其制备方法和用途
CN108026087B (zh)	2015-07-02	2021-06-04	中枢疗法公司	氨基嘧啶甲酮衍生物的柠檬酸盐
JP6903731B2 (ja) *	2016-07-07	2021-07-14	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	強力で選択的なｒｏｃｋ阻害剤としてのラクタム、環状尿素、およびカルバメート、およびトリアゾロン誘導体
US11014927B2 (en)	2017-03-20	2021-05-25	Forma Therapeutics, Inc.	Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
KR102586510B1 (ko)	2018-02-13	2023-10-12	길리애드 사이언시즈, 인코포레이티드	Pd-1/pd-l1 억제제
AU2019255750B2 (en)	2018-04-19	2021-10-21	Gilead Sciences, Inc.	PD-1/PD-L1 inhibitors
AU2019301811B2 (en)	2018-07-13	2022-05-26	Gilead Sciences, Inc.	PD-1/PD-L1 inhibitors
JP7450610B2 (ja)	2018-09-19	2024-03-15	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	ピルビン酸キナーゼｒの活性化
MA53668B1 (fr)	2018-09-19	2024-06-28	Novo Nordisk Health Care Ag	Traitement de la drépanocytose avec un composé activant la pyruvate kinase r
JP7158577B2 (ja)	2018-10-24	2022-10-21	ギリアードサイエンシーズ，インコーポレイテッド	Ｐｄ－１／ｐｄ－ｌ１阻害剤
US12371421B2 (en)	2019-04-29	2025-07-29	Ribon Therapeutics, Inc.	Solid forms of a PARP7 inhibitor
US20220315545A1 (en) *	2019-07-10	2022-10-06	Bayer Aktiengesellschaft	Process of preparing 2-(phenylimino)-1,3-thiazolidin-4-ones
CN114286820A (zh) *	2019-08-21	2022-04-05	卡尔维斯塔制药有限公司	酶抑制剂
MA57202B1 (fr)	2019-09-19	2025-09-30	Novo Nordisk Health Care Ag	Compositions d'activation de la pyruvate kinase r (pkr)
EP4139298A4 (en)	2020-04-21	2024-05-22	Idience Co., Ltd.	Process for preparing a phthalazinone derivative and intermediates thereof
IL297464A (en)	2020-04-21	2022-12-01	Idience Co Ltd	Crystalline forms of phthalazinone compound
EP4161656A4 (en)	2020-06-05	2024-06-19	Kinnate Biopharma Inc.	Inhibitors of fibroblast growth factor receptor kinases
US12059419B2 (en)	2020-10-16	2024-08-13	Idience Co., Ltd.	Pharmaceutical composition comprising phthalazinone derivatives
WO2022159745A1 (en) *	2021-01-22	2022-07-28	Hibercell, Inc.	Gcn2 modulating compounds and uses thereof
US12128035B2 (en)	2021-03-19	2024-10-29	Novo Nordisk Health Care Ag	Activating pyruvate kinase R
CN115477640A (zh) *	2021-05-31	2022-12-16	由理生物医药（上海）有限公司	作为parp7抑制剂的哒嗪酮类化合物
EP4362978A4 (en) *	2021-06-28	2025-07-16	Merck Sharp & Dohme Llc	IL4I1 INHIBITORS AND METHODS OF USE

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2128175C1 (ru) *	1994-08-09	1999-03-27	Эйсай Ко., Лтд.	Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы
DE19921567A1 (de) *	1999-05-11	2000-11-16	Basf Ag	Verwendung von Phthalazine-Derivaten
GB0026505D0 (en) *	2000-10-30	2000-12-13	Kudos Pharm Ltd	Phthalazinone derivatives
US7151102B2 (en) *	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
JP2005501848A (ja) *	2001-08-15	2005-01-20	アイコスコーポレイション	２ｈ−フタラジン−１−オンおよびその使用方法
AUPS019702A0 (en) *	2002-01-29	2002-02-21	Fujisawa Pharmaceutical Co., Ltd.	Condensed heterocyclic compounds
NZ534712A (en) *	2002-02-19	2006-11-30	Ono Pharmaceutical Co	Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
JP4500161B2 (ja) *	2002-04-30	2010-07-14	クドスファーマシューティカルズリミテッド	フタラジノン誘導体
JPWO2004009556A1 (ja) *	2002-07-24	2005-11-17	杏林製薬株式会社	４−置換アリール−５−ヒドロキシイソキノリノン誘導体
US7449464B2 (en) *	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
JP4027406B2 (ja)	2003-03-12	2007-12-26	クドスファーマシューティカルズリミテッド	フタラジノン誘導体
WO2005049593A2 (en) *	2003-11-13	2005-06-02	Abbott Laboratories	N-acylsulfonamide apoptosis promoters
WO2006003147A1 (en) *	2004-06-30	2006-01-12	Janssen Pharmaceutica N.V.	Phthalazine derivatives as parp inhibitors
GB0419072D0 (en) *	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
GB0521373D0 (en) *	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
UY30639A1 (es) *	2006-10-17	2008-05-31	Kudos Pharm Ltd	Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US20100184770A1 (en) *	2006-12-20	2010-07-22	Glaxo Group Limited	Compounds
AU2008240679A1 (en) *	2007-04-23	2008-10-30	Novartis Ag	Phthalazine and isoquinoline derivatives with SLP receptor modulating activities
JP2010539149A (ja) *	2007-09-14	2010-12-16	アストラゼネカアクチボラグ	フタラジノン誘導体
US20100216799A1 (en) *	2007-10-11	2010-08-26	Glaxo Group Limited	Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists

2007
- 2007-12-20 RS RS20140059A patent/RS53196B/sr unknown
- 2007-12-20 MX MX2009007051A patent/MX2009007051A/es active IP Right Grant
- 2007-12-20 DK DK13191894.8T patent/DK2698062T3/en active
- 2007-12-20 RU RU2009128984/04A patent/RU2455286C2/ru not_active IP Right Cessation
- 2007-12-20 SI SI200731690T patent/SI2698062T1/sl unknown
- 2007-12-20 EP EP07869628.3A patent/EP2120579B1/en active Active
- 2007-12-20 PL PL13191894T patent/PL2698062T3/pl unknown
- 2007-12-20 MY MYPI20092727A patent/MY165570A/en unknown
- 2007-12-20 DK DK07869628.3T patent/DK2120579T3/da active
- 2007-12-20 JP JP2009544209A patent/JP5523837B2/ja not_active Expired - Fee Related
- 2007-12-20 CA CA2672868A patent/CA2672868C/en not_active Expired - Fee Related
- 2007-12-20 CN CN2007800518771A patent/CN101641014B/zh not_active Expired - Fee Related
- 2007-12-20 SG SG2012022745A patent/SG193664A1/en unknown
- 2007-12-20 SG SG2014013411A patent/SG2014013411A/en unknown
- 2007-12-20 SI SI200731369T patent/SI2120579T1/sl unknown
- 2007-12-20 CN CN201310512269.3A patent/CN103690542B/zh not_active Expired - Fee Related
- 2007-12-20 KR KR1020147010385A patent/KR101491998B1/ko not_active Expired - Fee Related
- 2007-12-20 PT PT131918948T patent/PT2698062E/pt unknown
- 2007-12-20 PT PT78696283T patent/PT2120579E/pt unknown
- 2007-12-20 UA UAA200907943A patent/UA97506C2/ru unknown
- 2007-12-20 HU HUE13191894A patent/HUE027641T2/en unknown
- 2007-12-20 NZ NZ598352A patent/NZ598352A/xx not_active IP Right Cessation
- 2007-12-20 NZ NZ577348A patent/NZ577348A/en not_active IP Right Cessation
- 2007-12-20 KR KR1020097013523A patent/KR101449436B1/ko not_active Expired - Fee Related
- 2007-12-20 WO PCT/US2007/088319 patent/WO2008083027A1/en not_active Ceased
- 2007-12-20 MX MX2013000244A patent/MX347085B/es unknown
- 2007-12-20 MY MYPI2012001663A patent/MY190838A/en unknown
- 2007-12-20 PL PL07869628T patent/PL2120579T3/pl unknown
- 2007-12-20 EP EP13191894.8A patent/EP2698062B1/en active Active
- 2007-12-20 ES ES07869628.3T patent/ES2442496T3/es active Active
- 2007-12-20 HR HRP20140115TT patent/HRP20140115T1/hr unknown
- 2007-12-20 PH PH1/2012/501544A patent/PH12012501544A1/en unknown
- 2007-12-20 AU AU2007340020A patent/AU2007340020B2/en not_active Ceased
- 2007-12-20 ES ES13191894.8T patent/ES2548353T3/es active Active
- 2007-12-20 BR BRPI0722070-7A2A patent/BRPI0722070A2/pt not_active IP Right Cessation
- 2007-12-27 US US11/964,822 patent/US20080161280A1/en not_active Abandoned
- 2007-12-28 TW TW096150907A patent/TWI429438B/zh not_active IP Right Cessation
2009
- 2009-06-25 DO DO2009000159A patent/DOP2009000159A/es unknown
- 2009-06-25 GT GT200900182A patent/GT200900182A/es unknown
- 2009-06-30 CR CR10901A patent/CR10901A/es unknown
- 2009-07-17 CO CO09074708A patent/CO6220961A2/es active IP Right Grant
- 2009-07-17 NO NO20092698A patent/NO20092698L/no not_active Application Discontinuation
- 2009-07-22 EC EC2009009530A patent/ECSP099530A/es unknown
2013
- 2013-07-10 JP JP2013144223A patent/JP2014001209A/ja active Pending

Also Published As

Publication number	Publication date
ECSP099530A (es)	2009-08-28
MY165570A (en)	2018-04-05
CA2672868A1 (en)	2008-07-10
HK1194922A1 (en)	2014-10-31
EP2698062A1 (en)	2014-02-19
MY190838A (en)	2022-05-12
EP2698062B1 (en)	2015-06-24
UA97506C2 (xx)	2012-02-27
CN103690542B (zh)	2015-11-18
RS53196B (sr)	2014-06-30
KR101491998B1 (ko)	2015-02-10
SG193664A1 (en)	2013-10-30
AU2007340020B2 (en)	2013-06-20
CO6220961A2 (es)	2010-11-19
RU2009128984A (ru)	2011-02-10
NZ598352A (en)	2013-08-30
CN103690542A (zh)	2014-04-02
DOP2009000159A (es)	2015-11-30
KR20090094116A (ko)	2009-09-03
CR10901A (es)	2009-07-23
AU2007340020A1 (en)	2008-07-10
EP2120579A4 (en)	2011-04-27
ES2442496T3 (es)	2014-02-11
HUE027641T2 (en)	2016-11-28
CN101641014B (zh)	2013-12-18
EP2120579B1 (en)	2013-11-13
KR20140056395A (ko)	2014-05-09
TW200840579A (en)	2008-10-16
EP2120579A1 (en)	2009-11-25
PL2120579T3 (pl)	2014-04-30
TWI429438B (zh)	2014-03-11
NZ577348A (en)	2012-04-27
MX2009007051A (es)	2009-07-10
JP5523837B2 (ja)	2014-06-18
WO2008083027A1 (en)	2008-07-10
PT2698062E (pt)	2015-10-19
US20080161280A1 (en)	2008-07-03
DK2698062T3 (en)	2015-09-14
CA2672868C (en)	2015-11-24
JP2010514785A (ja)	2010-05-06
RU2455286C2 (ru)	2012-07-10
GT200900182A (es)	2010-02-19
JP2014001209A (ja)	2014-01-09
PL2698062T3 (pl)	2015-12-31
DK2120579T3 (da)	2014-02-03
MX347085B (es)	2017-04-06
PT2120579E (pt)	2014-02-17
SG2014013411A (en)	2014-07-30
CN101641014A (zh)	2010-02-03
HRP20140115T1 (hr)	2014-03-14
NO20092698L (no)	2009-09-28
SI2120579T1 (sl)	2014-03-31
SI2698062T1 (sl)	2015-12-31
PH12012501544A1 (en)	2024-06-03
ES2548353T3 (es)	2015-10-15
KR101449436B1 (ko)	2014-10-14

Publication	Publication Date	Title
BRPI0722070A2 (pt)	2014-04-08	Inibidores de poli(adp-ribose)polimerase
LTPA2019522I1 (lt)	2019-12-27	Poli(ADP-ribozės)polimerazės (PARP) dihidropiridoftalazinono inhibitoriai
LTC2109608I2 (lt)	2019-05-10	Amidu pakeisti indazolai, kaip poli(ADP-ribozės)polimerazės (PARP) inhibitoriai
BRPI1007358A2 (pt)	2018-03-06	inibidores de poli (adp-ribose) polimerase (parp)
DK2069312T3 (da)	2013-02-04	Pyridazinonderivater
ES2527265T8 (es)	2015-04-20	Consola
BRPI0718796A2 (pt)	2014-02-18	Nucleotídeo
DE602007001549D1 (de)	2009-08-27	Substrathaltevorrichtung
EP2043672A4 (en)	2009-10-21	SELECTIVE INHIBITORS OF CASPASES
EP2115033A4 (en)	2012-04-04	POLYURETHANE
DE112007003149A5 (de)	2009-09-24	Spannfutter
DE602007009224D1 (de)	2010-10-28	R-cellular-systemen
EP1981070A4 (en)	2011-08-17	POLISHING CUSHIONS FOR CHEMICAL-MECHANICAL POLISHING
DE502006004094D1 (de)	2009-08-06	Bohrfutter
DE502006005977D1 (de)	2010-03-11	Baugruppenträger
DE112007000530A5 (de)	2008-12-04	Kopfplatte
DE502007001783D1 (de)	2009-12-03	Bauteilhalterung
FI7261U1 (fi)	2006-10-25	Hiomakone
DE602006019048D1 (de)	2011-02-03	EDDH enthaltende Entzunderungslösungen
FR2900477B3 (fr)	2008-04-18	Lunettes
EP2119010A4 (en)	2010-07-28	INTEGRATED CIRCUITS
SE0600253L (sv)	2007-01-16	Hållaranordning
FI7259U1 (fi)	2006-10-25	Työstökeskus
FR2899778B1 (fr)	2012-01-27	Console
SE0600721L (sv)	2007-10-01	Nyckelhållare

Legal Events

Date	Code	Title	Description
2017-10-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-10-30	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2019-03-19	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.